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Abstract
Background: Four species of human bocaviruses (HBoV1-4) have been identified based on phylogenetic analysis since its
first report in 2005. HBoV1 has been associated with respiratory disease, whereas HBoV2-4 are mainly detected in enteric
infections. Although the prevalence of HBoVs in humans has been studied in some regions, it has not been well addressed
globally.
Methodology/Principal Findings: Cross-reactivity of anti-VP2 antibodies was detected between HBoV1, 2, 3, and 4 in
mouse and human serum. The prevalence of specific anti-VP2 IgG antibodies against HBoV1-4 was determined in different
age groups of healthy individuals aged 0-70 years old in Beijing, China, using a competition ELISA assay based on virus-like
particles of HBoV1-4. The seroprevalence of HBoV1-4 was 50%, 36.9%, 28.7%, and 0.8%, respectively, in children aged 0-14
years (n=244); whereas the seroprevalence of HBoV1-4 was 66.9%, 49.3%, 38.7% and 1.4%, respectively, in healthy adults
($15 years old; n=142). The seropositive rate of HBoV1 was higher than that of HBoV2, HBoV3, and HBoV4 in individuals
older than 0.5 years. Furthermore, IgG seroconversion of HBoV1 (10/31, 32.3%), HBoV2 (8/31, 25.8%), and HBoV3 (2/31, 6.5%)
was found in paired sera collected from children with respiratory tract infections who were positive for HBoV1 according to
PCR analysis.
Conclusions/Significance: Our data indicate that HBoV1 is more prevalent than HBoV2, HBoV3, and HBoV4 in the
population we sampled in Beijing, China, suggesting that HBoV species may play differential roles in disease.
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Introduction
Human bocavirus (HBoV), a member of the Parvoviridae family,
is a potential etiologic agent of respiratory disease and of acute
gastroenteritis [1–11]. Based on phylogenetic analysis of viral
genomes, four species of HBoVs (HBoV1-4) have been identified
[1,7–9]. HBoV1 is associated with respiratory tract diseases
[1,2,12–14]. HBoV2 and 3 have been detected in the respiratory
tract, but are associated mainly with stool samples [8–11,15,16].
HBoV4 has been detected in enteric infections [9]. However, as
HBoVs are frequently co-detected with other viral infections in
patients with respiratory or enteric infections, the exact roles of
HBoVs in pathogenicity are unclear.
HBoVs are small, non-enveloped viruses with a linear single-
stranded DNA genome of approximately 5 kb in length. The
genome consists of four open reading frames (ORFs), encoding
two nonstructural proteins (NS1 and NP1) and two overlapping
capsid proteins (VP1 and VP2) [1]. The lack of a well-established
cell culture system or animal model to propagate HBoVs has
hampered understanding of the infection and pathogenicity of
HBoVs. Studies have shown that the VP2 protein harbors the
major antigen of HBoV and can form the empty virus-like
particles (VLPs) which mimic HBoV virions morphologically and
antigenically. The VP2 VLPs have been successfully used as
antigens for detecting antibodies against HBoVs [17–22].
Currently, detection of HBoVs nucleic acid is primarily used to
estimate the prevalence of HBoV species in clinical samples. The
prevalence of HBoV1, which is mainly detectable in children
under two years old [23], is 2–19% in patients suffering from acute
respiratory tract infections (ARTIs) worldwide as detected by PCR
analysis [1,2,10,12,13,23,24]. The detection rate of HBoV2,
HBoV3, and HBoV4 DNA in stool samples have been reported
as 1-26%, 0.4-5%, and 0-2%, respectively [8,9,23,25]. The
prevalence of HBoV2-4 is higher in children than in adults
according to some, but not all studies [8,9,11,16,25]. However, the
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the general population as subclinical infections can occur and
HBoV persists in the nasopharynx [26–29].
Seroepidemilogical investigations of healthy populations may be
more useful than patient studies in assessing the prevalence,
spread, and exposure distribution of HBoVs in the population.
The seroprevalence data also allow a comparison between the
frequency of natural infection and the frequency of this virus in
individuals with infections [30]. However, previous seroepidemio-
logical studies of HBoVs have mainly focused on HBoV1. HBoV1
specific IgG antibodies were frequently detected in children, with
a seropositive rate ranging from 40.7%-60% for children , four
years old and up to .85% for those $ four years old [19]. The
seropositive rate of HBoV1 VP2-specific IgG antibodies is about
94% in healthy adults [18]. However, Kantola et al. recently
showed cross-reactivity between the VP2 VLPs of HBoV1-4,
which can largely affect the seropositive data of HBoV species.
They showed that after depletion of cross-reactive antibodies, the
approximate seroprevalences of HBoV1-4 in adults were 59%,
34%, 15%, and 2%, respectively [22]. However, the samples used
in that study were only collected from healthy young people with
a narrow range of age, including 115 subjects aged 21-32 years
from Finland and 80 subjects aged 18-20 years from Pakistan.
Given that the prevalence of a virus infection may vary by age as
well as geographically, there remains to be a need to estimate the
seroprevalence of HBoVs based on the detection of antibodies
against HBoV1-4 from data of a more complete age range and
from other global, geographic regions.
In the present study, we used a competition ELISA (cELISA)
assay to estimate the seroprevalence of HBoV1-4 in healthy
Chinese individuals ranging in age from 0 to 70 years in Beijing,
China. We also compared the seroconversion of anti-HBoV IgG
antibodies in 31 paired serum samples from ARTI children who
were positive for HBoV1 by PCR. Our findings provide
informative data for evaluating the prevalence and pathologic
roles of HBoVs.
Results
Production of HBoV1-4 VLPs
To produce antigens that can be used to evaluate the
seroprevalence of HBoVs, the VP2 genes of HBoV1-4 were
expressed in baculovirus to generate VLPs. The VP2 genes of
HBoV1, HBoV2, and HBoV3 were amplified from stool samples
by PCR. The sequences of these genes were verified by
phylogenetic analysis (Figure 1A). The VP2 genes from respiratory
and stool specimens were very similar in sequences. The HBoV1
strain 111-BJ07 used in this study clustered with the reference
HBoV1 strain ST2 [1], with homologies of 99.8%. The HBoV2
strain 211-BJ07 has 97.9% identity with the reference HBoV2
strain PK-2255 [7]. The HBoV3 strain 46-BJ07 has 99.6%
identity with reference HBoV3 strain W471 [8]. As we did not find
any HBoV4 positive samples, the VP2 gene of HBoV4 was
synthesized according to the sequence of HBoV4 strain NI-385
[9].
The VP2 proteins of HBoV1-4 were expressed in insect cells
using a baculovirus expression system. The generation of HBoV
VLPs was verified by ultracentrifuge-purification and electron
microscopy (EM). Typical parvovirus-like particles of 22–24 nm in
size, similar to the particles of infectious parvovirus virions, were
visualized under EM (data not shown). The purified VLPs of
HBoV1, 2, 3 and 4 were also reactive to murine antisera specific
for the VP2 protein of the respective HBoV species in Western
blot assays (Figure 1B).
Cross-reactivity of HBoVs
Sequence alignment showed a high amino acid identity of VP2
between HBoV species, with 77.5% identity between HBoV1 and
HBoV2, 77.7% identity between HBoV1 and HBoV3, 77.5%
identity between HBoV1 and HBoV4, 89.4% identity between
HBoV2 and HBoV3, 88.5% identity between HBoV2 and
HBoV4, and 90.9% identity between HBoV3 and HBoV4 (data
not shown), indicating possible cross-reactivity between HBoV
species. To evaluate the potential cross-reactivities, we examined
the reactivity between the HBoV1-4 VLPs and purified mouse
antisera against HBoV1, 2, 3, and 4 VP2 using Western blot and
ELISA assays.
Western blot analysis showed that the antisera against HBoV1,
2, 3, and 4 reacted with 400 ng of VLPs of each HBoV species, as
indicated by detection of specific bands of 60 kD in size
(Figure 2A). Similar cross-reactivities were also detected by ELISA
assays (Figure 2B). Mouse sera against HBoV1, 2, 3, and 4 reacted
strongly with the homologous VLPs. Moreover, all four antisera
reacted with the heterologous HBoV VLPs when the concentra-
tion of the mice antiserum was high (.0.25 mg/mL). No
significant reactivity was observed with the human parvovirus
B19 VP2 or influenza virus H5 hemaglutinin (H5) antiserum
(Figure 2B). These results are consistent with those reported by
Kantola et al [22].
Screening of Control Human Serum Samples
To develop ELISA assays that can detect antibodies against
HBoV species, we first sought to identify HBoV-positive and -
negative sera samples using Western blot analysis. To obtain
negative sera samples, we tested the reactivity of sera samples
collected from infants aged 0-6 months who visited Beijing
Children’s Hospital for regular health check-ups against HBoV
VLPs. Only the samples that were negative for HBoV1, 2, 3, and 4
VLPs simultaneously were selected as the negative samples. The
negativity of those samples was confirmed using a competition
ELISA (cELISA) assay, in which the absorbance value at 450 nm
did not change significantly with or without competition assays
(Figure 3). Serum samples identified by cELISA as positive for
individual HBoV species were obtained from 3 children and 4
adults and used as positive controls. However, we did not obtain
a serum sample that was positive only for HBoV4 based on the
assay; we used a sample from an adult that was IgG positive for
HBoV1, HBoV2 and HBoV4. To determine the concentration of
VLPs required for exhaustive antibody competition of HBoV1-4,
the serum samples were monocompeted with concentrations of
HBoV1, 2, 3, or 4 VLPs ranging from 0-32 mg/mL (Figure 3). We
found that HBoV VLPs concentration of 16 mg/mL was the
effective concentration to perform the VLP-based competition
assays.
Development of ELISA Methods for Detecting Anti-HBoV
IgG Antibodies
To determine the seroprevalence of HBoV1, 2, 3, and 4 in
humans, we developed an ELISA protocol for detecting IgG
antibodies against HBoV1-4 using VLPs as coating antigens. The
concentration of the coated VLPs (0.125 mg/mL) for this ELISA
assay was optimized using chessboard titration tests. The positive
sera and negative sera showed different results at 1:200 serum
dilutions. As the results obtained using lower serum dilutions were
similar to those obtained at 1:200 (data not shown), the 1:200
dilution was used in subsequent ELISA analysis of serum samples.
To determine the cut-off values for the ELISA, we determined the
mean values and standard deviation of negative sera for HBoV1,
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the mean absorbance at 450 nm of the negative sera plus three-
folds the standard deviation as the cut-off values, as previously
described [19,31]. For HBoV1, 2, 3 and 4, the cut-off values were
0.344, 0.304, 0.321, and 0.31, respectively. A sample was
considered positive for HBoV1, 2, 3, or 4 if its absorbance at
450 nm was above the cut-off value of the respective species in
ELISA.
As there are cross-reactivities between HBoV species in ELISA
assay, we developed a cELISA assay to evaluate the seropreva-
lence of each HBoV species. We evaluated the specificity of this
protocol using heterologous competition assays with parvovirus
B19 and human parvovirus 4 (PARV4) VP2. Neither human
parvovirus B19 nor PARV4 VP2 inhibited the reactivity of IgG
against HBoV1, 2, 3, or 4 in the serum from adults or children
(Figure 3). These results suggest that there is no antigenic cross-
reactivity between HBoVs VP2 and human parvovirus B19 VP2
or between HBoVs VP2 and PARV4 VP2. To confirm the
specificity of this ELISA protocol, we tested sera from 15 adults
that were positive for human parvovirus B19. In the HBoV VLP
ELISA, we did not detect false-positive signals for HBoVs (data
not shown).
Seroprevalence of HBoVs in Adults
To determine the seroprevalence of HBoV1-4 in adults, we used
the HBoV VLPs ELISA method to detect IgG antibodies against
HBoV1-4 in 142 serum samples collected from healthy individuals
15-70 years old. Without competition, more than 90% samples
were positive for HBoV1, HBoV2, and HBoV3; 73 (51.4%)
samples were positive for HBoV4 (Table 1). However, these IgG
seroprevalences decreased with competition by VLPs of heterol-
ogous HBoV species (Figure 4). The cELISA resulted in
seroprevalences of 66.9%, 49.3%, 38.7%, and 1.4%, for HBoV1,
2, 3, and 4 IgG, respectively. The seropositive rate of HBoV1 was
higher than that of HBoV2, HBoV3, and HBoV4
(x
2=23,P,0.01) (Table 1 and Figure 5).
Twenty-fiveofthe142(17.6%)adultsamplesthatwerepositivefor
IgG antibody against HBoV1, 2, and 3, and 17 (12%) that were
positiveforHBoV4intheELISAwerenegativeforIgGagainstall4
HBoVsinthecELISA.Amongpositiveserumsamplesagainstsingle
Figure 1. Production of virus-like particles of human bocaviruses. (A) Phylogenetic analysis of human bocavirus (HBoV) species. The
phylogenetic tree with 1,000 bootstrap replicates was generated using the Clustal W and MegAlign programs in the MEGA 4.0 software package
and based on the complete sequences of the VP2 gene of the HBoV strains used in this study. The VP2 genes of the HBoV1, 2, and 3 were
obtained from stool samples from children with acute diarrhea in Beijing and are marked with red triangles. HBoV1 strains ST1, ST2, and
TW2888_06; HBoV2 strains W153, PK-2255, LZ55602, and 277-BJ07; HBoV3 strains W471 and W855; and HBoV4 strains NI-385 were used as
reference sequences (GenBank accession numbers DQ000495, DQ000496, EU984237, EU082213, FJ170279, GU301645, JQ240471, EU918736,
FJ948861, NC012729, respectively). (B) Western blot analysis of the HBoV1-4 VLPs detected by mouse antisera against HBoV1, 2, 3, and 4 VP2,
respectively.
doi:10.1371/journal.pone.0039644.g001
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Seroprevalence of HBoVs in Children
The seropositive rates of HBoV1, 2, and 3 in children increased
with age according to results from the ELISA without competition.
The rates for HBoV1, 2, and 3 reached to 77.9%, 61.1%, and
58.9%, respectively, in the age group 5-14 years. The seropreva-
lence for HBoV4 among children aged 0-0.5 year and 5-14 years
increased from 10.3% to 31.6% (Table 1). However, according to
results of the cELISA, the seroprevalences of HBoV1, 2, 3, and 4
IgG decreased about 10-27% (Table 1, Figure 5). The seropre-
valence among children aged 0-0.5 years and children aged 5-14
years increased from 6.9% to 60%, 6.9% to 49.5%, and 6.9% to
38.9% for HBoV1, HBoV2, and HBoV3, respectively, in the
cELISA.
Of note, among 29 infants aged 0-6 months, two (6.9%) were
positive for HBoV1, 2, and 3 IgG, and one (3.4%) was positive for
HBoV4. The detection of HBoVs IgG antibodies among children
aged 0-6 months may be due to the presence of maternal
Figure 2. Cross-reactivity between antisera against VP2 proteins of HBoV1, 2, 3, or 4 with virus-like particles of each HBoV species.
(A) Western blot analysis. Mouse antiserum against HBoV1, 2, 3, or 4 was diluted at 1:1000 and incubated with the virus-like particles of HBoV1, 2, 3,
and 4, respectively. The loading amount of VLPs for each lane was 400 ng. (B) ELISA assay. Mouse antisera against HBoV1, 2, 3, or 4 were tested for
reactivity to virus-like particles of HBoV1, 2, 3, and 4, respectively. Rabbit antiserum against human parvovirus B19 VP2 and mouse antiserum against
influenza virus H5 hemaglutinin (HA) were used as controls. The Abs 450 nm values for each concentration of coating antigens are shown on the y-
axis; the protein concentrations of antigens coated in ELISA assay are shown on the x-axis.
doi:10.1371/journal.pone.0039644.g002
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VLPs. VLP concentrations are shown on the x-axis. Sera from three children and four adults were positive for HBoV1, 2, 3, or 4. The negative sera
samples that were from infants aged 0-6 months, were identified using Western blot analysis. Human parvovirus B19 and PARV4 VP2 proteins were
used as controls.
doi:10.1371/journal.pone.0039644.g003
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than that of HBoV2, 3, or 4 in the age groups of 0.5-2 years, 2-5
years, and 5-14 years (x
2=10.1,P,0.01; x
2=9.3, P,0.01;
x
2=8.42,P,0.05, respectively). Based on the results of the
cELISA, there were 38 (15.6%) individuals positive for HBoV1,
nine (3.7%) for HBoV2, and two (0.8%) for HBoV3 among
positive serum samples against single HBoV species. Notably, the
two samples positive for HBoV4 IgG were also positive for
HBoV1, 2, and 3 IgG.
Seroprevalence and Seroconversion Among Children
with Acute HBoV1 Infection
To characterize the antibody response after HBoV infection
further, we measured the IgG antibody in 31 pairs of sera samples
that were collected from children with ARTIs. All these children
were positive for HBoV1 according to PCR analysis. Based on
cELISA, the seroprevalences of HBoV1, 2, 3, and 4 in acute-phase
sera were 29%, 25.8%, 16.1%, and 0%, respectively. Of the 31
samples, ten (32.3%) showed an IgG seroconversion for HBoV1,
eight (25.8%) for HBoV2, two (6.5%) for HBoV3, and none for
HBoV4 (Table2). Two pairs of sera showed concurrent serocon-
versions to HBoV1 and HBoV2, and one pair showed concurrent
seroconversions to HBoV1, HBoV2, and HBoV3. In addition,
absorbance at 450 nm increasing in the convalescent-phase serum
was observed in seven children (22.6%) who were positive for
HBoV1 IgG and eight (25.8%) children who were positive for
HBoV2 IgG positive at the acute-phase.
Discussion
In this study, we evaluated the cross-reactivity of mouse antisera
against HBoV1, 2, 3, and 4 VP2 with VP2 VLPs for four species of
human bocaviruses. Considerable cross-reactivity was found
among the four HBoV species. However, human IgG antibodies
against HBoV did not cross react with human parvovirus B19 and
PARV4. These findings are consistent with those of a previous
report [22], suggesting that to obtain accurate data of the
seroprevalences of the different HBoV species, it is necessary to
correct for cross-reactivity between the four HBoVs. Comparison
of the VP2 protein sequences of HBoV1-4 revealed a high degree
of similarity. These similarities may account for the cross-reactivity
of these viruses, and should be confirmed through epitope analysis.
Human parvovirus B19 and PARV4 have no antigen cross-
reactivity with HBoVs, suggesting that human parvovirus B19 and
PARV4 antibodies do not interfere with the HBoV seroprevalence
results. The specificity of human bocavirus VLP-based ELISA
with human sera has also been demonstrated with human
parvovirus B19 VP2 and PARV 4 VP2 by Kantola et al [22].
We used a VLP-based ELISA to assess the seroprevalence of
HBoV1-4 in healthy individuals in Beijing, China, ranging from
0 to 70 years old. Our results show that the seroprevalences of
HBoV1, 2, and 3 range from 40.3-67.8% in children 0.5-2 years
old and are up to 100% in adults. To eliminate the interference of
antibody cross-reactivity, the results were corrected with a cE-
LISA. The results of our cELISA suggest that the seroprevalences
of HBoVs are significantly lower than those obtained without
competition, especially in adults. These findings further indicate
a high degree of antigenic cross-reactivity between HBoV1-4. Our
findings are consistent with those of a recent study of Finish and
Pakistani individuals, in which the seroprevalences of HBoVs
decreased after depletion of heterologous HBoV reactive anti-
bodies [22].
Our results from the cELISA are lower than those previously
reported for HBoV1 in adults and children [18,19,32], where
HBoV1 antibodies against HBoV1 VP2 were detected by ELISA.
Hence, the seroprevalence of HBoVs may be overestimated due to
the serological cross-reactivity among the four HBoV species in
previous studies. However, according to our cELISA results, the
seroprevalence of HBoV1-3 in Beijing adults is somewhat higher
than that reported in Finnish and Pakistani adults [22]. This
disparity may be attributed to the difference of geographical
location [22].
Our age stratification data indicates that HBoVs circulate
widely in the human population, and the primary infection with
HBoV1-3 occurs in children aged six months and older after the
maternal antibodies have waned. The seropositive rates of IgG
antibodies against HBoV2, 3 and 4 were lower than that of
HBoV1 in individuals of $0.5 years old. These data indicate that
Table 1. Immunoglobulin G (IgG) seroprevalences of 4 human bocaviruses among healthy individuals without/with antigen
competition.
Age (years) HBoV1, HBoV2 HBoV3 HBoV4
All chidren (n=244) 166
a/122
b (68
c/50
d) 119/90 (48.8/36.9) 121/70 (49.6/28.7) 55/2 (22.5/0.8)
Children by age
0–0.5 (n=29) 8/2 (27.6/6.9) 3/2 (10.3/6.9) 5/2 (17.2/6.9) 3/1 (10.3/3.4)
0.5–2 (n=62) 4/30 (67.8/48.4) 25/18 (40.3/29) 27/14 (43.5/22.6) 10/0 (16.1/0)
2–5 (n=58) 42/33 (72.4/56.9) 33/23(56.9/39.7) 33/17 (56.9/29.3) 15/1 (25.9/1.7)
5–14 (n=95) 74/57 (77.9/60) 58/47 (61.1/49.5) 56/37 (58.9/38.9) 30/0 (31.6/0)
All adults (n=142) 141/95 (99.3/66.9) 137/70 (96.5/49.3) 137/55 (96.5/38.7) 73/2 (51.4/1.4)
Adults by age
15–44 (n=47) 46/28 (97.9/59.6) 45/21 (95.7/44.7) 46/17 (97.9/36.2) 25/0 (53.2/0)
45–59 (n=47) 47/32 (100/68.1) 47/27 (100/57.4) 47/20 (100/42.6) 31/2 (66/4.3)
$60 (n=48) 48/35 (100/72.9) 45/22 (93.8/45.8) 44/18 (91.7/37.5) 17/0 (35.4/0)
aNumber of positive samples without antigen competition.
bNumber of positive samples with antigen competition.
cPercentage of positive samples without antigen competition.
dPercentage of positive samples with antigen competition.
doi:10.1371/journal.pone.0039644.t001
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whereas HBoV2-4 do not seem to have a major impact on HBoV
infections. This finding agrees with reports on HBoVs prevalence
obtained from most parts of the world using DNA analysis
[10,14,16]. Of note, our finding that the seroprevalence of HBoV4
is much lower than that of HBoV1-3 is consistent with the rare
detection of HBoV4 DNA in clinical samples [9]. Overall, the
seroprevalence of HBoVs indicated by results of the cELISA
decreased less in children than in adults in comparison to the
results without competition, indicating that HBoV infections are
more specific in children, especially for HBoV1 [22]. These results
suggest that HBoV species may play differential roles in disease.
Our results show that 17.6% of the adults who were positive for
IgG against HBoV1, 2, 3, or 4 based on the ELISA results were
negative for IgG against all four HBoVs based on the cELISA
results. This finding may be due to antibody waning in the
Figure 4. IgG reactivity of 244 sera from healthy children and of 142 sera from healthy adults with VLPs of HBoV1-4 (indicated on
the x axis). The sera were not competed (A), or competed with heterologous VLPs of the other three HBoVs (B) prior to ELISA assays. The net
reactivity was calculated as the raw absorbance value subtracted with the corresponding residual absorbance value from homologous competition.
The mean of serum absorbance value are marked with red line. The IgG cut-off values of HBoV1 (0.344), HBoV2 (0.304), HBoV3 (0.321) and HBoV4
(0.31) are shown for reference.
doi:10.1371/journal.pone.0039644.g004
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[20,33].
To assess the antibody response of HBoV1-4 IgG in children
with acute respiratory tract infections, we used cELISA to
determine the seroconversion rate of 31 paired sera from children
who were positive for HBoV1 according to PCR analysis. We
found that the HBoV1-specific seroprevalence was higher in
convalescent sera than in acute sera. However, heterotypic
seroconversion against HBoV2 and HBoV3 was also observed.
Moreover, for some patients who were positive for HBoV1 and
HBoV2 IgG at the acute phase, the absorbance value was higher
in convalescent sera. These data may suggest the concurrent
production of antibodies against HBoV2 and 3 during the
infection of HBoV1, as it has been shown that B-cell memory
can be boosted either by the homologous virus or by heterologous,
yet immunological related virus [20,34,35].
Overall, our findings suggest a differential prevalence of HBoV
species in healthy individuals aged 0-70 years old. HBoV1 appears
to be the dominant species responsible for HBoV infections among
HBoV1, 2, 3, and 4 in Beijing, China. The seroprevalence of
HBoV1-3 increased with age in children. Our study provides
a basis for future evaluation of the epidemiology, genotype
distribution, and pathogenesis of HBoVs worldwide.
Materials and Methods
Serum Specimens
Serum specimens were collected from 386 healthy individuals
aged 0 to 70 years in 2008; 244 specimens were from infants and
children who visited Beijing Children’s Hospital for regular health
check-ups. The 142 specimens from adults were provided by the
Beijing Blood Center. Exclusion criteria for all subjects included
pregnancy, any abnormalities in renal and liver function tests,
HIV/AIDS, sexual transmitted diseases, tumor, recurrent or acute
infection, and medication. None of the subjects had any
respiratory infection for at least three months prior to the blood
samples being taken. In addition, paired acute-phase (at the time
of admission) and convalescent -phase (2 weeks after disease onset)
serum samples were collected from 31 children (median age 17
months; range of 1 month to 9 years) with acute lower respiratory
tract infections (ALRTIs) when they were hospitalized at the
Beijing Children’s Hospital. The DNA of HBoV1, but not
HBoV2-4, was detected in the nasopharyngeal aspirates of these
31 patients at the time of admission by nested PCR and sequence
analysis using primers targeting the viral proteins (VP) 1/2 region
[9]. All serum samples were stored at 280uC prior to use.
Written informed consent was obtained from all participants or
guardians on behalf of children. This study was approved by the
ethical review committee of the Institute of Pathogen Biology,
Chinese Academy of Medical Sciences.
Phylogenetic Analysis
The full-length VP2 genes of HBoV1-4 were used for virus-
like particle (VLP) production in this study. HBoV1-3 VP2
genes were amplified from HBoV-positive stool specimens (111-
BJ07, 211-BJ07, and 46-BJ07; GenBank accession numbers:
JQ240469, JQ240470 and HM132056) [15]. HBoV1 is
1,629 bp (nt 3,373-5,001 according to HBoV1 strain ST1,
GenBank accession number DQ000495), HBoV2 is 1,617 bp (nt
3,306-4,922 according to HBoV2 strain PK2255, GenBank
accession number FJ170279), and HBoV3 is 1,620 bp (nt 3,410-
5,029 according to HBoV3 strain W471, GenBank accession
number EU918736) in length. The VP2 genes of HBoV4
(1626 bp in length, nt3331-4956 based on HBoV4 strain NI-
385, GenBank accession number NC012729) were synthesized
by Sangon Biotech (Shanghai, China). These genes were
verified by phylogenetic analysis using the Clustal W and
MegAlign programs in the MEGA 4.0 software package [36].
The phylogenetic tree with 1,000 bootstrap replicates was
generated based on the complete sequences of the VP2 genes
used in this study and reference sequences from GenBank.
HBoV1 strains ST1, ST2, and TW2888_06; HBoV2 strains
W153, PK-2255, LZ55602, and 277-BJ07; HBoV3 strains
W471 and W855; and HBoV4 strains NI-385 were used as
reference sequences (GenBank accession numbers DQ000495,
DQ000496, EU984237, EU082213, FJ170279, GU301645,
JQ240471, EU918736, FJ948861, NC012729, respectively).
Figure 5. Seropositive rates of IgG antibodies against HBoV
species in different age groups. IgG antibodies against HBoV1, 2, 3,
and 4 were detected by competition ELISA at a dilution of 1:200. All
serum samples were grouped based on age, as indicated by the x-axis
labels.
doi:10.1371/journal.pone.0039644.g005
Table 2. HBoV1-4 IgG seroconversion in 31 paired sera samples that were collected from HBoV1-positive children with acute
respiratory tract infections.
HBoV species Acute-phase serum Convalescent-phase serum Seroconversion
HBoV1 9
a (29)
b 19 (61.3) 10 (32.3)
HBoV2 8 (25.8) 16 (51.6) 8 (25.8)
HBoV3 5 (16.1) 7 (22.6) 2 (6.5)
HBoV4 0 (0) 0 (0) 0 (0)
a.Number of positive samples.
b.Percentage of positive samples.
doi:10.1371/journal.pone.0039644.t002
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The full-length VP2 genes of HBoV1, 2, 3, and 4 were cloned
into the baculovirus expression vector pFastbac1 and expressed
using Bac-to-BacH Baculovirus Expression System (Invitrogen,
Carlsbad, CA), according to the manufacturer’s protocol. VLPs
were obtained as previously described [17,37]. High Five cells
(Invitrogen) were infected with recombinant baculoviruses at
a multiplicity of infection (MOI) of five and harvested after three
days. Cells were suspended in 25 mM NaHCO3 solution at 2610
7
cells/mL and kept on ice for 30 min. After centrifugation at
18,000 rpm for 10 min at 4uC, (NH4)2SO4 was added to the
supernatants at a final concentration of 20% (w/v). Precipitants
were harvested by centrifugation and dissolved in CsCl solutions
with densities of 1.4 g/mL in Tris-EDTA buffer (10 mmol/L Tris,
pH 8.7, 1 mmol/L EDTA, and 0.5% Triton X-100). After
centrifugation at 35,000 rpm and 18uC for 39 h in a SW41 rotor
centrifuge (Beckman Coulter, Fullerton, CA), the fractions were
analyzed by SDS-PAGE and Western blot using mouse sera
against HBoV VP2 proteins. A Tecnai12 transmission electron
microscope (FEI, Hillsboro, OR) at 80 kV was used to verify the
morphology of the VLPs. SDS-PAGE and Western blot analysis
were used to identify the VLPs [18].
Recombinant VP2 proteins of HBoV1, 2, 3 and 4 were also
expressed in E. coli Rosetta (DE3) (Novagen, Madison,WI,) cells
and purified as previously described [37]. The genes used in
prokaryotic cloning were the same as those used in a baculovirus
expression system. The recombinant antigens were used to
immunize mice to produce antibodies (see below).
As controls, human parvovirus B19 VP2 was expressed, as
described previously [38], using the construct pFastBac1B19VP2
provided by Dr. Xiaohui Zou at the National Institute for Viral
Disease Control and Prevention, Chinese Center for Disease
control and Prevention. Additionally, the PARV4 VP2 gene
(1,659 bp in length, nt 3,464-5,122 based on the NC_007018
reference sequence) was synthesized by Sangon Biotech (Shanghai,
China) and cloned into baculovirus vector pFBGP67-His [39].
The recombinant baculoviruses were generated in Sf9 cells using
the Bac-to-BacH Baculovirus Expression System (Invitrogen)
protocol provided by the manufacturer. High Five cells were
infected with recombinant baculovirus expressing PARV4 VP2
gene at a MOI of five. The infected cells were collected three days
post-infection and purified using a HisTrap HP 1 ml column (GE
Healthcare, Waukesha, WI). The concentrations of all purified
protein were determined using the Pierce BCA Protein Assay Kit
(Thermo Scientific, Rockford, IL) and stored at 280uC prior to
use.
ELISA
ELISA was used to determine the anti-HBoV antibodies, as
described elsewhere [40]. The purified HBoV VLPs were used as
coating antigen (0.125 mg/mL). The absorbance of each serum
sample was read at 450 nm and the mean values of the duplicate
samples were calculated. Sera pooled from ten samples showing
HBoV-specific IgG responses were used as the internal references
in all experiments.
Analysis of Cross-reactivity between HBoV Species
To minimize false positive results of the ELISA assay due to
impurities in immunizing and coating antigens, the coating
antigen and the protein used to prepare mouse antibodies were
derived from a baculovirus expression system and a prokaryotic
expression system. BALB/c mice were injected subcutaneously
with the purified proteins obtained from E. coli. This study was
carried out in accordance with the animal experiment regulations
of the Chinese government. All animal experiments were
performed in the facilities of the Institute of Laboratory Animal
Sciences (ILAS), Chinese Academy of Medical Sciences (CAMS).
All experimental procedures were approved (license number
SCXKJ2009-0017) and supervised by the Animal Protection and
Usage Committee of ILAS, CAMS. Sera collected from the
treated mice were purified using protein-G sepharose columns (GE
Healthcare, Waukesha, WI) and purified IgG antibody were
quantified using Pierce BCA Protein Assay Kit (Thermo
Scientific). The purified mouse IgG antibodies were serially
diluted from 8 mg/mL to 0.008 mg/mL. Sera from pre-immune
mice served as the negative control. Rabbit antiserum against
human parvovirus B19 (a gift from Dr. Xia Xiao of National
Institute for Viral Disease Control and Prevention, Chinese
Center for Disease control and Prevention) and mice antiserum
against influenza virus H5 hemaglutinin (HA) [39] were used as
unrelated controls. The cross-reactivity between HBoV1, 2, 3, and
4 was tested using Western blot analysis and ELISA.
VLP-based Competition ELISA Assays
To measure antibodies specific to VP2 antigen of an individual
HBoV species (HBoV1, 2, 3, or 4), antibodies in serum samples
were absorbed with heterologous VLPs of the other three HBoVs,
as previously described [22]. Briefly, HBoV VLPs were serially
diluted from 32 mg/mL to 0.5 mg/mL to determine the concen-
tration needed for effective competition between cross-reactive
antibodies. For detection of specific HBoV antibodies, three
heterologous HBoV VLPs of 16 mg/mL were added to a 1:200
dilution of plasma [17] and incubated for 2 hr at 4uC prior to
performing the ELISA assay. In parallel with the heterologous
competition, human sera samples were used to compete with VLP
that was homologous to the immobilized antigen. The absorbance
at 450 nm was residual absorbance value. Net absorbance values
were calculated by subtracting the residual absorbance value from
the raw absorbance value read at 450 nm [22].
Statistical Analysis
Seropositive rates were evaluated using x
2 tests. A P value
#0.05 was considered significant.
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